Iovance Biotherapeutics, Inc.
IOVA
$2.21
$0.083.51%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.20% | 92.73% | 6,798.46% | 15,189.21% | 12,385.07% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.20% | 92.73% | 6,798.46% | 15,189.21% | 12,385.07% |
| Cost of Revenue | 22.08% | 80.64% | 585.04% | 943.37% | 626.22% |
| Gross Profit | 7.18% | 1,354.96% | 93.63% | 824.98% | 798.45% |
| SG&A Expenses | -12.15% | -4.72% | 39.92% | 42.14% | 45.88% |
| Depreciation & Amortization | -7.44% | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.50% | 30.60% | 44.00% | 31.65% | 24.23% |
| Operating Income | -0.78% | -11.64% | -2.97% | 28.60% | 24.75% |
| Income Before Tax | -10.11% | -11.27% | -3.16% | 34.82% | 26.04% |
| Income Tax Expenses | -58.22% | 236.35% | -30.54% | 188.57% | -22.28% |
| Earnings from Continuing Operations | -9.23% | -14.99% | -2.82% | 32.50% | 26.56% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.23% | -14.99% | -2.82% | 32.50% | 26.56% |
| EBIT | -0.78% | -11.64% | -2.97% | 28.60% | 24.75% |
| EBITDA | 0.62% | -12.06% | -2.65% | 31.77% | 26.85% |
| EPS Basic | 9.00% | 2.08% | 15.22% | 43.33% | 40.47% |
| Normalized Basic EPS | 13.29% | 5.27% | 15.11% | 44.14% | 40.05% |
| EPS Diluted | 9.00% | 2.08% | 15.22% | 43.33% | 40.47% |
| Normalized Diluted EPS | 13.29% | 5.27% | 15.11% | 44.14% | 40.05% |
| Average Basic Shares Outstanding | 20.04% | 17.45% | 21.28% | 19.12% | 23.37% |
| Average Diluted Shares Outstanding | 20.04% | 17.45% | 21.28% | 19.12% | 23.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |